Considering the substantial effect of BPE on NF-κB inhibition, it might hopefully be used as a complimentary for overcoming the limitation of those aforementioned NF-κB therapeutics in the treatment of severe pneumonia inflammation. This evidence concerns the gene NFKB1 and susceptibility to pneumonia measurement.